Dossier
clinicaltrials
trial early
A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis
Key claim: TQ05105, a JAK2 inhibitor, is being evaluated in a clinical trial for the treatment of moderate and high-risk myelofibrosis.
Abstract
Q05105 tablet is a Janus kinase 2 (JAK2) inhibitor, which can be used to treat JAK2 target related diseases, such as moderate or high-risk multiple myelofibrosis
Why this matters
TQ05105 adds another candidate to the growing list of JAK2 inhibitors being tested in myelofibrosis, an indication already served by ruxolitinib, fedratinib, pacritinib, and momelotinib. While the mechanism is not novel, additional JAK2 inhibitors may differentiate on selectivity, anemia/thrombocytopenia profiles, or combinability — relevant questions to track as trial data emerge.